)
Visual
earnings real time
HBM
HBM (2142) investor relations material
HBM H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary27 Aug, 2025
Executive summary
Achieved significant milestones in H1 2025, including major global collaborations, robust financial growth, and advancement of clinical and preclinical programs in immunology, oncology, metabolic, and CNS diseases.
Entered landmark strategic partnerships with AstraZeneca, Otsuka, and Windward Bio, securing substantial upfront, milestone, and royalty payments, enhancing global reach and pipeline value.
Expanded platform-based collaborations and incubated ventures in innovative therapeutic areas.
Financial highlights
Revenue rose 327.5% year-over-year to US$101.3 million in H1 2025, mainly from molecule license and research & technology fees.
Net profit surged to US$73.0 million from US$1.4 million in H1 2024.
R&D costs increased to US$18.0 million, reflecting pipeline advancement.
Cash and cash equivalents reached US$320.7 million as of June 30, 2025.
Basic and diluted EPS were US$0.09, up from US$0.00 year-over-year.
Outlook and guidance
Confident in continued global expansion and value realization through innovation and partnerships, with plans to accelerate clinical trials and expand into immunology and inflammation.
Focus on developing assets from proprietary platforms and expanding global collaborations.
Plans to further optimize discovery efficiency and accelerate portfolio value.
HBM7008: Revised development/commercialization plan
AstraZeneca upfront payment's contribution to revenue
Élancé Therapeutics: Unique competitive advantages
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 386
Profit fell 16% to RMB48.9B, but cost cuts and a 75% payout ratio were maintained. - 386Net profit and revenue fell on lower oil prices and weak margins, despite improved cash flow.
- DNLM
Sales and digital growth, margin expansion, and strategic investments drive strong FY25 results. - DNLMSales up 3.8% to £1,771m, profit before tax £211m, digital sales 40%, market share 7.9%.
- 9412
Profits and equity improved, with upward revisions to full-year forecasts and new subsidiaries added. - NVDA
AI is transforming enterprises by enabling intent-driven innovation and technology-first strategies. - DNLMH1 sales up 3.6% to £926m; digital mix 41%; PBT to hit lower end of consensus.
- CRW
Double-digit growth, strong cash flow, and new leadership drive confidence for FY25. - 7011
Strong revenue and profit growth in FY2025, with raised guidance and key divestiture impact. - 8053
Profit attributable to owners dipped 1.9% despite higher revenues and strong FX gains.
Next HBM earnings date
H2 202530 Mar, 2026
HBM
Next HBM earnings date
H2 202530 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
HBM Holdings Limited is a China-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative antibody therapeutics. The company utilizes its proprietary antibody technology platforms to develop a pipeline of monoclonal antibodies targeting various diseases, including cancer and autoimmune disorders. HBM Holdings conducts research and clinical development independently and through strategic partnerships in both domestic and international markets. The company is headquartered in Shanghai, China, and its shares are listed on the HKEX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage